We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Prostate Cancer in Black and White U.S. Veterans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00007540
Recruitment Status : Completed
First Posted : January 1, 2001
Last Update Posted : January 21, 2009
Information provided by:
VA Office of Research and Development

Brief Summary:
Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940?s, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.

Condition or disease
Prostate Cancer Prostatic Neoplasms

  Show Detailed Description

Study Type : Observational
Official Title: Study of Prostate Cancer in Black and White U.S. Veterans
Study Start Date : April 1998
Estimated Study Completion Date : September 2000

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Veterans who undergo prostate biopsy where biopsy results are positive or PSA less than 10Ng/ml.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00007540

United States, Illinois
Vamc - Chicago-Lakeside, Il
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
VA Office of Research and Development

ClinicalTrials.gov Identifier: NCT00007540     History of Changes
Other Study ID Numbers: 709D
First Posted: January 1, 2001    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: February 2003

Keywords provided by VA Office of Research and Development:
Prostate cancer
CAG repeat sequence

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Radiation-Protective Agents